Please login to the form below

Not currently logged in
Email:
Password:

New Accounts, February, 2009 - PR & Med Ed

New pharmaceutical account wins notified to us by the winning agency for the period December 2008 to January 2009 inclusive

New pharmaceutical account wins notified to us by the winning agency for the period December 2008 to January 2009 inclusive:

 

CLIENT

PRODUCT

THERAPEUTIC AREA

WINNING AGENCY

AstraZeneca RECENTIN Recurrent glioblastoma multiforme and colorectal cancer IMC Medical Communication
AstraZeneca ZD4054 Prostate cancer IMC Medical Communication
Baxter Europe Advate and FEIBA Haemophilia Ashley Communications
Roche Pegasys Hepatitis C and B Ketchum
Sanofi-aventis/ Bristol-Myers Squibb n/a Cardiovascular Medaxial
SPD Development Company Clearblue digital pregnancy test with conception indicator Women's health IMC Medical Communication
Typharm Dermatology portfolio Dermatology echo
TOPRA Corporate n/a Ash Healthcare
 Wyeth  ReFacto Haemophilia ROAD 

  

Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may not be involved with some of the products listed in other ways, or in domestic, overseas or international markets.

To submit an entry for New Accounts, email new_accounts@pmlive.com

5th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics